Results 241 to 250 of about 31,914 (284)
Some of the next articles are maybe not open access.
European Heart Journal - Cardiovascular Pharmacotherapy, 2020
AIMS This study compared the risk of major bleeding between atrial fibrillation (AF) patients who took non-vitamin-K antagonist oral anticoagulants (NOACs) and antiepileptic drugs (AEDs) concurrently and those who took only NOACs.
Chun-Li Wang +8 more
semanticscholar +1 more source
AIMS This study compared the risk of major bleeding between atrial fibrillation (AF) patients who took non-vitamin-K antagonist oral anticoagulants (NOACs) and antiepileptic drugs (AEDs) concurrently and those who took only NOACs.
Chun-Li Wang +8 more
semanticscholar +1 more source
Epistaxis and Dabigatran, a New Non-Vitamin K Antagonist Oral Anticoagulant
Acta Otorrinolaringologica (English Edition), 2014Dabigatran is a new non-vitamin K antagonist (VKA) anticoagulant with anti-thrombin action, with supposedly fewer haemorrhagic complications. However, there are actually no established agents to reverse its effect, nor specific coagulation time tests for monitoring it.An observational prospective study was developed, noting epidemiological, clinical ...
Francisco Javier, García Callejo +5 more
openaire +2 more sources
Thrombosis and Haemostasis, 2015
SummaryThe acute phase of venous thromboembolism (VTE) treatment focuses on the prompt and safe initiation of full-dose anticoagulation to decrease morbidity and mortality. Immediate management consists of resuscitation, supportive care, and thrombolysis for patients with haemodynamically significant pulmonary embolism (PE) or limb-threatening deep ...
Christopher M, Hillis, Mark A, Crowther
openaire +2 more sources
SummaryThe acute phase of venous thromboembolism (VTE) treatment focuses on the prompt and safe initiation of full-dose anticoagulation to decrease morbidity and mortality. Immediate management consists of resuscitation, supportive care, and thrombolysis for patients with haemodynamically significant pulmonary embolism (PE) or limb-threatening deep ...
Christopher M, Hillis, Mark A, Crowther
openaire +2 more sources
Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients
The American Journal of Cardiology, 2020Four non-vitamin K antagonist oral anticoagulants (NOACs) are approved for use to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF). However, data are limited regarding the use of NOACs in the obese population. This manuscript summarizes current concepts regarding obesity in patients with AF and reviews in depth ...
Stephen Y, Wang, Robert P, Giugliano
openaire +2 more sources
Safe administration of non-vitamin K antagonist oral anticoagulants
Nurse Prescribing, 2017Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. More than 1 million people in the UK have AF, and it is more prevalent in older people. It increases the risk of stroke fivefold ( Stroke Association, 2016a ). In 2009, non-vitamin K antagonist anticoagulants (NOACs) were integrated into clinical practice for the treatment of ...
openaire +1 more source
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
Journal of Thrombosis and Thrombolysis, 2018Intracardiac thrombus most commonly develops in the left atrial appendage (LAA) and left ventricle (LV) in the setting of atrial fibrillation (AF) and post-myocardial fibrillation (MI), respectively. Current guidelines recommend that patients with post-MI LV or LAA thrombus should be treated with vitamin K antagonist (VKA).
Eiman Ghaffarpasand +3 more
openaire +2 more sources
Postgraduate Medical Journal, 2014
Abstract Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic or haemorrhagic complications.
Karan, Saraf +5 more
openaire +3 more sources
Abstract Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic or haemorrhagic complications.
Karan, Saraf +5 more
openaire +3 more sources
[Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Ugeskrift for laeger, 2018Non-vitamin K oral anticoagulants (NOACs) are alternatives to vitamin K antagonists and provide consistent anticoagulation with equal or better clinical outcome and no need for routine monitoring. Bleeding is a feared complication of anticoagulants. Until recently, no specific agent has been available for reversal of NOACs.
Frederik Uttenthal, Larsen +2 more
openaire +1 more source
Non–vitamin K antagonist oral anticoagulant reversal: hope is on the horizon
The American Journal of Surgery, 2016Non-vitamin K oral anticoagulants have become an attractive alternative to warfarin when patients require anticoagulation. Until recently, one of the biggest challenges to these agents was the lack of specific reversal of their anticoagulation when bleeding occurs or urgent/emergent procedures are required.This article is a narrative review of peer ...
openaire +2 more sources